Evidence map›Paper›PMID 34840680›Full record

ArticleJournal of ophthalmic & vision research

Carrier Status for p.Gly61Glu and p.Arg368His

Ali Heshmati, Peyman Taghizadeh, Hamid Ahmadieh, Mehdi Yaseri, Fatemeh Suri, Mahsa Alizadeh, Marjan Dadashzadeh, Hajar Khatami, Monireh Moradkhah Navi, Parisa Zamanparvar and 2 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmic & vision research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ali Heshmati *School of Biology, University College of Science, University of Tehran, Tehran, Iran.
Peyman Taghizadeh *School of Biology, University College of Science, University of Tehran, Tehran, Iran.
Hamid AhmadiehOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehdi YaseriDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh SuriOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahsa AlizadehAstaneh Health Center, Astaneh, Guilan, Iran.
Marjan DadashzadehRasht Health Center, Rasht, Guilan, Iran.
Hajar KhatamiAnzali Health Center, Anzali, Guilan, Iran.
Monireh Moradkhah NaviTalesh Medical Center, Talesh, Guilan, Iran.
Parisa ZamanparvarLahijan Medical Center, Lahijan, Guilan, Iran.
Hassan BehboudiDepartment of Ophthalmology, Guilan University of Medical Sciences, Rasht, Iran.
Elahe ElahiSchool of Biology, University College of Science, University of Tehran, Tehran, Iran.
University of Tehran · IRShahid Beheshti University of Medical Sciences · IRGuilan University of Medical Sciences · IRIslamic Azad University, Lahijan Branch · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo estimate carrier frequencies of

methodsPopulation-based screenings were performed. DNA was extracted from saliva samples of 1036 individuals from Talesh and 3029 individuals from the east of Guilan. P.Gly61Glu and p.Arg368His screenings were performed, respectively, by RFLP and ARMS-based PCR protocols. For confirmation, the DNA of individuals with mutations was sequenced using the Sanger protocol.

resultsNine individuals from Talesh (0.86%; 95%CI: 0.45-1.64%) carried the p.Gly61Glu mutation, and 73 from the east of Guilan (2.41%; 95%CI: 1.91-3.04%) carried p.Arg368His. There was no significant difference in frequencies between urban and rural regions of the various cities, nor among four cities within the east of Guilan.

conclusionThe frequencies of p.Gly61Glu carriers in Talesh and of p.Arg368His carriers in the east of Guilan were within the 95% confidence interval of a previous study based on screenings of fewer individuals. The reliability of the recent estimates is higher, as the confidence interval for p.Gly61Glu decreased from 6.5% to 1.19% and the interval for p.Arg368His decreased from 4% to 1.13%. Based on the new findings, the maximum expected frequency of p.Gly61Glu carriers in Talesh is 1.64%, and of p.Arg368His carriers in the east of Guilan is 3%. The need for performing premarital screenings in the respective cities can be evaluated.

Indexed as

CYP1B1GuilanIranp.Arg368Hisp.Gly61GluPrimary Congenital Glaucoma

Identifiers

PMID34840680
PMCPMC8593531
OpenAlexW3210042787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.